{"id":458,"date":"2026-08-14T12:08:20","date_gmt":"2026-08-14T10:08:20","guid":{"rendered":"https:\/\/www.pqra.gr\/market-access-for-obesity-medicines-in-europe-the-reimbursement-reckoning\/"},"modified":"2026-08-27T11:35:40","modified_gmt":"2026-08-27T09:35:40","slug":"market-access-for-obesity-medicines-in-europe-the-reimbursement-reckoning","status":"publish","type":"post","link":"https:\/\/www.pqra.gr\/el\/market-access-for-obesity-medicines-in-europe-the-reimbursement-reckoning\/","title":{"rendered":"Market Access for Obesity Medicines in Europe: The Reimbursement Reckoning"},"content":{"rendered":"

The science of obesity treatment has raced ahead of the systems that pay for it. GLP-1 medicines have transformed clinical expectations, but across Europe reimbursement remains patchy, restrictive and politically fraught. For manufacturers, the hard problem is no longer approval — it is convincing budget-holders to fund a highly effective therapy for a condition that affects a very large share of the population.<\/strong><\/p>\n\n

Approval is the easy part<\/h2>\n

The regulatory pathway is now well trodden. Semaglutide 2.4 mg (Wegovy) received its EU marketing authorisation in January 2022 for chronic weight management, and in 2024 the EMA supported a label update reflecting the SELECT cardiovascular-outcomes trial, which reported a 20% relative reduction in major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity. Tirzepatide (Mounjaro) gained a positive EU opinion for weight management in late 2023, and an oral GLP-1 option for weight management has since reached the EU market. A new generation of oral agents is advancing through global regulatory review.<\/p>\n

That cardiovascular indication matters commercially: it reframes some of these products as cardiovascular risk-reduction therapies rather than “weight-loss drugs,” which is often the difference between a payer conversation that can happen and one that cannot.<\/p>\n\n

The affordability problem in numbers<\/h2>\n

The tension is structural. According to Eurostat, around half of EU adults were overweight in 2022 and roughly one in six was living with obesity. The economic burden is measured in the hundreds of billions of euros a year across Europe. When an eligible population is that large, even a well-priced therapy produces a budget-impact figure that alarms any health system — and payers respond by narrowing access rather than opening it.<\/p>\n\n

A patchwork of national positions<\/h2>\n

There is no single European answer. The current landscape ranges from outright exclusion to cautious, capped reimbursement:<\/p>\n